Kuros Aktie
| 25,18CHF | -0,76CHF | -2,93% |
WKN DE: A2ALS5 / ISIN: CH0325814116
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6 | 6 | 5 | 4 | 178 |
| Umsatz pro Mitarbeiter in Mio. EUR | 2,30 | 3,00 | 6,71 | 18,89 | 0,68 |
Bilanz (in Mio. CHF) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 33 | 31 | 27 | 45 | 65 |
| Summe Anlagevermögen | 63 | 57 | 49 | 44 | 42 |
| Summe Aktiva | 96 | 88 | 76 | 88 | 107 |
Bilanz (in Mio. CHF) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 19 | 19 | 19 | 30 | 40 |
| Summe Eigenkapital | 77 | 69 | 57 | 59 | 67 |
| Summe Passiva | 96 | 88 | 76 | 88 | 107 |
Adresse
| Wagistrasse 25, 8952 Schlieren | |
| Telefon | +41 (44) 733-47-47 |
| Fax | +41 (44) 733-47-40 |
| Internet | http://kurosbio.com |
Management
|
Christopher T. Fair
Chief Executive Officer |
|
Clemens A. van Blitterswijk
Chairman |
|
Daniel Geiger
Chief Financial Officer |
|
Florence Barrère de Groot
Vice President-Research & Development |
|
Joe Ross
Senior VP-Marketing & Business Development |
|
John Griffin
Chief Commercial Officer |
|
Joost D. de Bruijn
Executive Director & President-Innovation |
|
Katherine Sage
Senior Vice President-Medical & Clinical Affairs |
|
Kimberley A. Elting
Director |
|
Laura Rosa
Senior Vice President-Global Human Resources |
|
Luuk van Dijk
Manager-Medical & Scientific Affairs |
|
Marcel Borger
Head-Quality & Regulatory Affairs |
|
Oliver Walker
Independent Non-Executive Director |
|
Philippe Saudan
Chief Development Officer |
|
Sjoerd Musters
Chief Operating Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.